Literature DB >> 34021346

Response to Zhang and Zhang.

Mengyun Qiang1, Xing Lv1.   

Abstract

Entities:  

Keywords:  deep learning; locoregionally advanced nasopharyngeal carcinoma; prognostic system

Year:  2021        PMID： 34021346      PMCID： PMC8634524          DOI： 10.1093/jnci/djab099

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

1.  Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.

Authors:  Su-Mei Cao; Qi Yang; Ling Guo; Hai-Qiang Mai; Hao-Yuan Mo; Ka-Jia Cao; Chao-Nan Qian; Chong Zhao; Yan-Qun Xiang; Xiu-Ping Zhang; Zhi-Xiong Lin; Wei-Xiong Li; Qing Liu; Fang Qiu; Rui Sun; Qiu-Yan Chen; Pei-Yu Huang; Dong-Hua Luo; Yi-Jun Hua; Yi-Shan Wu; Xing Lv; Lin Wang; Wei-Xiong Xia; Lin-Quan Tang; Yan-Fang Ye; Ming-Yuan Chen; Xiang Guo; Ming-Huang Hong
Journal:  Eur J Cancer       Date:  2017-02-16       Impact factor: 9.162

2.  A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02).

Authors:  M Frikha; A Auperin; Y Tao; F Elloumi; N Toumi; P Blanchard; P Lang; S Sun; S Racadot; J Thariat; M Alfonsi; C Tuchais; A Cornely; A Moussa; J Guigay; J Daoud; J Bourhis
Journal:  Ann Oncol       Date:  2018-03-01       Impact factor: 32.976

3.  NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

Authors:  A Dimitrios Colevas; Sue S Yom; David G Pfister; Sharon Spencer; David Adelstein; Douglas Adkins; David M Brizel; Barbara Burtness; Paul M Busse; Jimmy J Caudell; Anthony J Cmelak; David W Eisele; Moon Fenton; Robert L Foote; Jill Gilbert; Maura L Gillison; Robert I Haddad; Wesley L Hicks; Ying J Hitchcock; Antonio Jimeno; Debra Leizman; Ellie Maghami; Loren K Mell; Bharat B Mittal; Harlan A Pinto; John A Ridge; James Rocco; Cristina P Rodriguez; Jatin P Shah; Randal S Weber; Matthew Witek; Frank Worden; Weining Zhen; Jennifer L Burns; Susan D Darlow
Journal:  J Natl Compr Canc Netw       Date:  2018-05       Impact factor: 11.908

4.  Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.

Authors:  Ying Sun; Wen-Fei Li; Nian-Yong Chen; Ning Zhang; Guo-Qing Hu; Fang-Yun Xie; Yan Sun; Xiao-Zhong Chen; Jin-Gao Li; Xiao-Dong Zhu; Chao-Su Hu; Xiang-Ying Xu; Yuan-Yuan Chen; Wei-Han Hu; Ling Guo; Hao-Yuan Mo; Lei Chen; Yan-Ping Mao; Rui Sun; Ping Ai; Shao-Bo Liang; Guo-Xian Long; Bao-Min Zheng; Xing-Lai Feng; Xiao-Chang Gong; Ling Li; Chun-Ying Shen; Jian-Yu Xu; Ying Guo; Yu-Ming Chen; Fan Zhang; Li Lin; Ling-Long Tang; Meng-Zhong Liu; Jun Ma
Journal:  Lancet Oncol       Date:  2016-09-27       Impact factor: 41.316

5.  Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.

Authors:  R L Hong; C F Hsiao; L L Ting; J Y Ko; C W Wang; J T C Chang; P J Lou; H M Wang; M H Tsai; S C Lai; T W Liu
Journal:  Ann Oncol       Date:  2018-09-01       Impact factor: 32.976
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.